JP2019532991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532991A5 JP2019532991A5 JP2019523058A JP2019523058A JP2019532991A5 JP 2019532991 A5 JP2019532991 A5 JP 2019532991A5 JP 2019523058 A JP2019523058 A JP 2019523058A JP 2019523058 A JP2019523058 A JP 2019523058A JP 2019532991 A5 JP2019532991 A5 JP 2019532991A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- site
- administered
- chlorhexidine
- biofilm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 29
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 10
- 229960003260 chlorhexidine Drugs 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000003876 biosurfactant Substances 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 210000005252 bulbus oculi Anatomy 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000000855 fungicidal effect Effects 0.000 claims description 2
- 239000000417 fungicide Substances 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 230000002262 irrigation Effects 0.000 claims description 2
- 238000003973 irrigation Methods 0.000 claims description 2
- 239000000644 isotonic solution Substances 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims 1
- 230000003214 anti-biofilm Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413116P | 2016-10-26 | 2016-10-26 | |
| US62/413,116 | 2016-10-26 | ||
| PCT/US2017/058510 WO2018081411A2 (en) | 2016-10-26 | 2017-10-26 | Materials and methods for the control of biofilm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532991A JP2019532991A (ja) | 2019-11-14 |
| JP2019532991A5 true JP2019532991A5 (enExample) | 2019-12-26 |
Family
ID=62024010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523058A Pending JP2019532991A (ja) | 2016-10-26 | 2017-10-26 | バイオフィルムの制御のための材料および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200253898A1 (enExample) |
| EP (1) | EP3532043A4 (enExample) |
| JP (1) | JP2019532991A (enExample) |
| KR (1) | KR20190077433A (enExample) |
| CN (1) | CN110381933A (enExample) |
| AU (1) | AU2017347819A1 (enExample) |
| BR (1) | BR112019008411A2 (enExample) |
| CA (1) | CA3041816A1 (enExample) |
| IL (1) | IL266180A (enExample) |
| MX (1) | MX2019004879A (enExample) |
| WO (1) | WO2018081411A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220103A (es) | 2019-08-10 | 2022-05-05 | Locus Ip Co Llc | Entrega olfatoria de compuestos terapéuticos al sistema nervioso central |
| CN111299267B (zh) * | 2020-02-12 | 2021-10-22 | 上海交通大学 | 一种基于群感效应的供水管网生物膜控制方法及其应用 |
| DE202020004186U1 (de) * | 2020-10-05 | 2020-10-21 | Christian Fleischhammel | Antiinfektive Arzneiform zur Herstellung einer Nasenspülung gegen COVID-19 |
| EP4221681A1 (de) * | 2020-09-29 | 2023-08-09 | Lighthouse Pharma GmbH | Antiinfektive arzneiformen zur herstellung einer nasenspülung |
| US20230241126A1 (en) * | 2022-01-28 | 2023-08-03 | Ndal Mfg Inc | Compositions and methods for disruption of biofilms using fractionated honey |
| CN119351279B (zh) * | 2024-12-24 | 2025-03-28 | 中国科学院烟台海岸带研究所 | 一株褐藻酸降解菌的拮抗细菌及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105979940A (zh) * | 2013-12-12 | 2016-09-28 | 创新技术股份有限公司 | 控制感染的材料和方法 |
-
2017
- 2017-10-26 US US15/763,219 patent/US20200253898A1/en not_active Abandoned
- 2017-10-26 BR BR112019008411A patent/BR112019008411A2/pt not_active Application Discontinuation
- 2017-10-26 CA CA3041816A patent/CA3041816A1/en not_active Abandoned
- 2017-10-26 WO PCT/US2017/058510 patent/WO2018081411A2/en not_active Ceased
- 2017-10-26 KR KR1020197014810A patent/KR20190077433A/ko not_active Ceased
- 2017-10-26 CN CN201780080538.XA patent/CN110381933A/zh active Pending
- 2017-10-26 AU AU2017347819A patent/AU2017347819A1/en not_active Abandoned
- 2017-10-26 EP EP17864747.5A patent/EP3532043A4/en not_active Withdrawn
- 2017-10-26 JP JP2019523058A patent/JP2019532991A/ja active Pending
- 2017-10-26 MX MX2019004879A patent/MX2019004879A/es unknown
-
2019
- 2019-04-22 IL IL266180A patent/IL266180A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532991A5 (enExample) | ||
| Chen et al. | Nanomaterials-based photothermal therapy and its potentials in antibacterial treatment | |
| US11559503B2 (en) | Materials and methods for controlling infections | |
| JP2017503852A5 (enExample) | ||
| KR20190105014A (ko) | 아세트산 및 차아염소산을 포함하는 조성물 및 생물막을 치료하는 방법 | |
| CN110072391A (zh) | 抗微生物组合物 | |
| KR101286038B1 (ko) | 항생 물질의 주사제 및 그 투여액 | |
| US20200253898A1 (en) | Materials and methods for the control of biofilm | |
| WO2014205159A1 (en) | Poloxamer based inhalation composition | |
| CA3100966A1 (en) | Inhibition of neurological disease | |
| US10076551B2 (en) | Method for treating interstitial lung disease | |
| US20160317467A1 (en) | Method of treating or preventing infection | |
| US20140377356A1 (en) | Inhalation Composition for Treating Respiratory Tract Infections | |
| Shah et al. | Sustained Delivery Of Silver-Based Antimicrobials Using Shell Crosslinked Knedel-Like And Acetalated-Dextran Nanoparticles For The Treatment Of Pulmonary Infections | |
| Cohen et al. | Poster 76-A Comparison of Systane® Lubricant Eye Drops Versus Refresh Tears® Lubricant Eye Drops When Used as Supportive Therapy with Restasis® Ophthalmic Emulsion | |
| WO2020005785A1 (en) | Pyrogen binding composition and use of same in treatment and prevention of sepsis | |
| Orizondo | Antibacterial Perfluorocarbon Ventilation: A Novel Treatment Method for Bacterial Respiratory Infections. | |
| US20140377355A1 (en) | Levofloxacin Inhalation Composition | |
| HK40017056A (en) | Materials and methods for the control of biofilm |